- Home
- RLAY vs SRPT Comparison
RLAY vs SRPT Comparison
Compare RLAY & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RLAY | SRPT |
|---|---|---|
| Founded | 2015 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.5B |
| IPO Year | 2020 | 2000 |
Fundamental Metrics
Financial Performance| Metric | RLAY | SRPT |
|---|---|---|
| Price | $13.50 | $16.78 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 29 |
| Target Price | $19.50 | ★ $25.85 |
| AVG Volume (30 Days) | ★ 3.8M | 2.7M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.78 | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | $15,355,000.00 | ★ $2,198,237,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $324.03 | N/A |
| P/E Ratio | ★ N/A | $5.89 |
| Revenue Growth | ★ 53.44 | 15.58 |
| 52 Week Low | $2.83 | $10.42 |
| 52 Week High | $17.32 | $43.92 |
Technical Indicators
Market Signals| Indicator | RLAY | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 54.25 | 33.04 |
| Support Level | $11.75 | $15.70 |
| Resistance Level | $17.32 | $19.62 |
| Average True Range (ATR) | 0.94 | 1.09 |
| MACD | 0.01 | -0.39 |
| Stochastic Oscillator | 49.61 | 2.96 |
Price Performance
Historical ComparisonAbout RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.